Buprenorphine vs. Oxycodone: Chronic Pain Management for PI Cases

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 9 min read

Buprenorphine and oxycodone represent fundamentally different pharmacological approaches to managing chronic pain after traumatic injury. Understanding why a physician chooses a partial agonist over a full agonist — and what that signals about the case — is essential for PI attorneys.

Buprenorphine is a partial mu-opioid receptor agonist with a ceiling effect on respiratory depression, while oxycodone is a full mu-opioid receptor agonist without such a ceiling. In personal injury cases, buprenorphine increasingly appears in pharmacy records for chronic post-traumatic pain management, and its presence signals a deliberate clinical strategy to manage long-term pain with a safer pharmacological profile than traditional full-agonist opioids.

• Buprenorphine (Belbuca, Butrans) is FDA-approved for chronic pain and offers a ceiling effect on respiratory depression, reducing overdose risk
• Oxycodone (OxyContin, Roxicodone) is a full mu-agonist used for moderate-to-severe acute and chronic pain
• Both are DEA Schedule II (buprenorphine was moved to Schedule III for addiction treatment formulations, but remains Schedule II/III depending on indication and formulation)
• A transition from oxycodone to buprenorphine in the pharmacy record signals the physician is optimizing long-term safety while maintaining pain control
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report documenting the clinical rationale behind opioid transitions, including partial-agonist switches

Mechanism of Action

Oxycodone is a full mu-opioid receptor agonist. It binds to mu receptors with high affinity and produces dose-dependent analgesia, sedation, and respiratory depression. There is no pharmacological ceiling to its analgesic or respiratory-depressant effects — increasing the dose increases both pain relief and risk of adverse effects, including fatal respiratory depression.

Buprenorphine is a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist. As a partial agonist, it activates mu receptors but produces a submaximal response even at full receptor occupancy. This creates a clinically valuable ceiling effect — beyond a certain dose, additional buprenorphine does not increase respiratory depression, significantly reducing overdose risk. The kappa antagonism may also contribute to mood stabilization and reduced dysphoria.

Buprenorphine has extremely high mu-receptor binding affinity, meaning it tightly occupies opioid receptors and can displace other opioids. This pharmacological property is why buprenorphine is used both for chronic pain (Belbuca buccal film, Butrans transdermal patch) and for opioid use disorder treatment (Suboxone, Sublocade).

Side-by-Side Comparison

Clinical Significance for Personal Injury

Oxycodone in a PI pharmacy record is standard for acute and subacute post-traumatic pain. It indicates the injury was severe enough to warrant full-agonist opioid therapy, and its presence is clinically unremarkable in cases involving fractures, spinal injuries, post-surgical recovery, and severe soft tissue damage.

Buprenorphine appearing in the pharmacy record carries a different and increasingly important clinical signal. When a treating physician transitions a PI patient from oxycodone (or another full-agonist opioid) to buprenorphine for chronic pain, this decision reflects several clinical considerations: the injury has evolved from acute to chronic pain requiring long-term management; the physician is prioritizing overdose safety through the ceiling effect; and the patient may benefit from buprenorphine's more stable receptor kinetics, which produce less euphoria and potentially lower abuse liability.

Defense counsel sometimes attempts to characterize buprenorphine prescribing as evidence of opioid addiction rather than legitimate pain management. This argument is factually incorrect when the formulation prescribed is Belbuca or Butrans — these are FDA-approved specifically for chronic pain management, not for opioid use disorder. The prescribing indication, formulation, and dosing all distinguish pain management from addiction treatment.

When Physicians Choose One Over the Other

Physicians select oxycodone when:

• Acute or subacute pain requires immediate, dose-titratable full-agonist analgesia
• The expected treatment duration is weeks to months, not indefinite
• Post-surgical pain management requires rapid dose adjustments
• The patient has no contraindications to full-agonist opioid therapy

Physicians select buprenorphine when:

• Chronic post-traumatic pain requires long-term opioid management with a better safety profile
• The patient is being transitioned off full-agonist opioids while maintaining pain control
• Overdose risk mitigation is a clinical priority (polypharmacy, sleep apnea, elderly patients)
• The physician wants stable, around-the-clock analgesia with less euphoria and lower abuse potential
• The patient has demonstrated tolerance to full-agonist opioids and the physician is resetting opioid therapy

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "The oxycodone-to-buprenorphine transition is one of the most misunderstood patterns in PI pharmacy records. It is not evidence of addiction — it is evidence of sophisticated, guideline-concordant chronic pain management that prioritizes patient safety while maintaining analgesic efficacy."

Pharmacy Lien Documentation

Buprenorphine formulations for chronic pain (Belbuca, Butrans) are distinct from addiction-treatment formulations (Suboxone, Sublocade) in both their FDA labeling and their prescribing requirements. Attorneys should verify which formulation appears on the lien record and ensure the clinical narrative correctly characterizes the prescribing indication. The LienScripts platform documents each opioid transition with prescriber notes, diagnosis codes, and treatment rationale to prevent mischaracterization at settlement or trial.

For more on buprenorphine's role in PI cases, see Buprenorphine for Chronic Pain in Personal Injury. For a comprehensive overview of opioid prescribing standards, read Opioid Prescribing Guidelines in Personal Injury.